Advanced searches left 3/3

Breast Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 May 2022

* If you want to update the article please login/register

Breast Cancer Prevention and Screening Membership

Based on the analysis of women's individual risk factors and their involvement in structured screening, as well as reducing the incidence of the disease, the prevention strategy currently in place could be updated and enhanced in order to provide more details to women on breast cancer risk factors and their participation in organized screening, as well as lowering the incidence of the disease. Tyrer Cuzick, Mammorisk, and CANRISK are the new founding of the Cancer Risk Management Platform, which is designed to provide women with a breast cancer risk assessment and prevention consultation with a medical exam and the use of three breast cancer risk assessment and prevention tools: Tyrer Cuzick, Mammorisk, and CANRISK. The risk assessment and monitoring program are explained to the consultant, and when "actionable" risk factors are identified, customized assistance is offered. These questionnaires will also help monitor how the perception of risk is maintained over time and how this may influence primary and secondary prevention behaviors.

Source link: https://clinicaltrials.gov/ct2/show/NCT05258539


Inflammatory Breast Cancer (IBC) Registry

Patients with previously diagnosed inflammatory breast cancer, whether surgery or partially treated, can obtain paraffin tissue blocks, needle, plasma, whole blood, medical, and imaging results from patients with previously diagnosed inflammatory breast cancer, who have been treated or partially treated, but not satisfied in the IBC clinic in M. D. Anderson or participating cancer network sites, but do not have mastectomy or outpatient scans. To determine patients with specific breast cancer subtypes and toxins related to inflammation, we need oral swab, skin, and stool bacteria microbiome cultures to compare patients with specific breast cancer subtypes of care to determine changes in flora during treatment and toxicity.

Source link: https://clinicaltrials.gov/ct2/show/NCT00477100


A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

The aim of determining the effect of chemotherapy in patients with node positive breast cancer who do not have high recurrence rates by Oncotype DX is to determine the effect of chemotherapy in patients with node positive breast cancer patients with no recurrence scores above Oncotype DX. After the reveal of test findings and during a randomized trial, a study was conducted to determine the effect of managing With Oncotype DX on patient-reported anxiety prior to screening. V. To determine the impact of Oncotype DX on the initial management of node-positive, hormone receptor -positive, human epidermal growth factor receptor -2 -negative breast cancer, and breast cancer, see Figure 1. To compare patient-reported services for those randomized to chemotherapy versus no chemotherapy, compare patient-reported medications for those randomized to chemotherapy versus no chemotherapy. Patients' reported exhaustion and cognitive difficulties as a result of chemotherapy therapy versus no chemotherapy are two key issues cited by patients. After the publication of test findings and during the blinded trial, the aim was to determine the effects of Oncotype DX administration on patient-reported decision conflict, misperceptions regarding Oncotype DX testing, and survivor fears prior to screening. The presence of circulating tumor cells in two CTC platforms will be assessed at two separate time points to determine late recurrence in those who are still waiting for the primary outcome. To compare clinically reported menopausal status with status categorized by serum hormone measurements determined from baseline serum samples in women under age 55 years and to assess subsequent association with outcomes, refering to a more definite relationship with outcomes. Patients are treated with a protocol-approved chemotherapy regimen based on the patient's and/or physician preference. Patients are followed every three months for 1 year, every 6 months for four years, and then annually for 15 years after completion of study research.

Source link: https://clinicaltrials.gov/ct2/show/NCT01272037


Expanded Breast Cancer Registry and Tissue Repository

Any new diagnosis of breast cancer must be reported by institution and/or physicians to the New Mexico Tumor Registry. In addition, a tissue bank will be established for collecting paired tissue from patients diagnosed with breast cancer who have agreed to donate excess/extra tissue and blood for the Tissue Repository. This tissue bank will act as a repository for research into breast cancer risks, prognosis, and survival in women with breast cancer diagnosed in this institution.

Source link: https://clinicaltrials.gov/ct2/show/NCT00322894


Breast Cancer and Resistance Exercise Program (B-REP): A Feasibility and Acceptability Trial

A printed, individualized resistance-based physical fitness program would be included in the attention control arm. A total of 50 breast cancer survivors will be recruited from Rutgers Cancer Institute of New Jersey and assigned to one of two study arms. The intervention arm will determine the safety and acceptability of the intervention relative to the control arm, which will get a printed or digital copy of an individualized physical fitness plan. Both in-person and online data collection will take place. The interview will be from 45-to-60 minutes in length, and participants will be encouraged to share their experiences in the program.

Source link: https://clinicaltrials.gov/ct2/show/NCT04562233


Enhancing Shared Decision-Making in Breast Cancer

During decision-making visits, two sites will perform the RCT of 140 patients with MBC and 140 patients with EBC, comparing the use of SDM TPs during decision-making visits compared to TPs that were delivered post-decision-making. All clinical clinic locations will be able to provide health care services to patients with breast cancer patients with the Carevive Care Planning System. Patients and physicians will be able to investigate the patient's decision-making style, patient's desire for prognostic information therapies, and patient preferences regarding decision making together. The research coordinator will examine the electronic medical record for completion of the standard of care elements that are required for the production of TPs after the patient's permission. If this form has not been completed, the research coordinator may request form completion or complete this form within the EMR to ensure availability at the time of the treatment decision. If a decision is made at their initial visit, it will be necessary to ensure new patients get TPs from the beginning of the procedure prior to consent for patients approached by telephone. The clinical data will be imported directly into the Carevive platform by either the research coordinators or clinical staff at other locations that do not use EMR forms. We will allow a 1-month window around the initial 6-month survey and a 2-week window around the post-treatment study to accommodate patients who would like to complete surveys in-person.

Source link: https://clinicaltrials.gov/ct2/show/NCT03806738


Converting HR+ Breast Cancer Into an Individualized Vaccine

Patients will be on the study for a total of 5 months, including 4 months on active research intervention, breast surgery at week 16 and a one-month follow-up period after surgery. On week 2, at a dose of 8 Gy x 3 fractions every other day, all arms radiation therapy to the breast tumor will begin.

Source link: https://clinicaltrials.gov/ct2/show/NCT03804944


Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database

This research is being conducted to find out more about breast cancer hormone therapy's side effects, and if a person's genetic information can help us to determine what side effects a patient may have and how to handle them.

Source link: https://clinicaltrials.gov/ct2/show/NCT01937052


The Role of Histamine in Breast Cancer Bone Pain

To determine histamine levels in plasma in patients with bone metastases from breast cancer who have or have not been treated with palliative radiotherapy, it is helpful to compare histamine in plasma with pain scores in patients with bone metastases from breast cancer who have or have not been treated with palliative radiotherapy. To determine whether histamine system is involved in the onset of cancer-induced bone pain, it's likely that histamine system is involved. To determine the effects of pain relief following radiotherapy on bone structural properties such as bone mineral density and cortical thickness, as well as patient quality of life, physical, and psychological function. Participants are encouraged to submit blood samples for histamine level testing by enzyme-linked immunosorbent assay.

Source link: https://clinicaltrials.gov/ct2/show/NCT03529565

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions